Key Highlights
- Huntsville Hospital Health System signed a five-year commercial agreement.
- Huntsville is the first SAPPHIRE Study participant to convert to full commercial use.
- Salix Coronary Plaque utilisation increased after a pre-authorisation workflow was introduced at Tanner Health.
- An investor call was held on 26 October 2026.
Artrya Limited (ASX:AYA), a medical technology company commercialising its Salix AI-powered cloud platform for coronary artery disease, released its Appendix 4C and activities report for the quarter ended 30 September 2026 on 26 October 2026.
Huntsville agreement
Huntsville Hospital Health System, Artrya's largest customer to date, signed a five-year commercial agreement and became the first SAPPHIRE Study participant to convert to full commercial use.
US rollout
Northeast Georgia Health System began expanding beyond its launch site and Cone Health is progressing toward clinical deployment. Salix Coronary Plaque utilisation increased following implementation of a pre-authorisation workflow at Tanner Health in mid-September, with higher activity continuing into October.
SAPPHIRE and engagement
The SAPPHIRE study continues to support clinical evidence generation and commercial engagement, with participants and inbound health systems progressing commercial discussions. The company said all financial results are unaudited and in Australian dollars.
Commercial focus
Artrya said its commercial focus is on bringing more health systems live to increase the number of coronary CT angiography studies processed through Salix and on driving adoption of the reimbursed Salix Coronary Plaque module across those customers. The pre-authorisation workflow at Tanner Health addressed a reimbursement barrier to plaque assessment, and the capability is built into Salix and will be deployed as part of future customer implementations.
Why This Could Matter
A conversion from study participant to commercial customer shows how the study feeds into sales, and the workflow change at Tanner Health relates to how scans are authorised for payment.
Summing Up
Artrya (ASX:AYA) reported a five-year hospital agreement and rising Salix usage in the September 2026 quarter.






Please wait processing your request...